NOVOLIN 70/30 Drug Profile

Summary for Tradename: NOVOLIN 70/30

Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for NOVOLIN 70/30

Recent Clinical Trials for NOVOLIN 70/30

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Illinois at Chicago	Phase 2
State University of New York - Downstate Medical Center	Phase 4
University of California, San Francisco	N/A

See all NOVOLIN 70/30 clinical trials

Pharmacology for NOVOLIN 70/30

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOLIN 70/30 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOLIN 70/30 Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2008-02-10	Company disclosures

3) Low Certainty: US Patents for NOVOLIN 70/30 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2033-03-11	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2029-05-13	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991		2036-02-19	Patent claims search

International Patents for NOVOLIN 70/30

Country	Patent Number	Estimated Expiration
Ireland	61515
Spain	2030541
Hungary	T54064